Pen needles are an integral part of the diabetes treatment experience for patients who rely on injectable therapies. Nearly 30 years ago, Novo Nordisk launched the world’s first pen needle. Since then, we have strived to improve the injection experience for patients by developing progressively shorter and thinner needles. NovoFine® Plus, the company’s latest needle, is our shortest at 4 mm and features improvements that are designed to make injections more comfortable. Learn more about the Novo Nordisk family of pen needles below.

NovoFine® Plus is the latest needle advancement from Novo Nordisk. It is a 32G 4 mm pen needle that uses universal threading, which enables it to fit all currently available insulin pens and some GLP-1 receptor agonist pens. The ultra-short and ultra-thin 32G 4 mm needle is designed for less pain while maintaining strength and reducing the risk of bending or breakage.²

NovoFine® 32G Tip is a universal pen needle, which was launched in 2008.

NovoTwist® 32G Tip was designed exclusively for Novo Nordisk pens. NovoTwist® uses a 32G 5 mm needle and features a “twist and click” attachment.

NovoFine® Autocover® 30G is a needle with a safety shield designed for use in institutions. The automatic shield feature locks into place, concealing the needle both before and immediately after use, helping to prevent accidental needle-stick injuries.

For more information, please visit NovoNeedles.com.


Autocover®, NovoFine®, and NovoTwist® are registered trademarks and SuperFlow™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2017 Novo Nordisk All rights reserved. USA17NP02396 September 2017